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Abstract
The aim of this study is the comparison of 2 studies looking at the barriers to access of diabetes 
care and medicines in the Philippines and Vietnam. These studies used the Rapid Assessment Protocol 
for Insulin Access. Diabetes care is provided in specialized facilities and appropriate referral systems 
are lacking. In Vietnam, no problems were reported with regard to diagnostic tools, whereas this 
was a concern in the public sector in the Philippines. Both countries had high prices for medicines 
in comparison to international standards. Availability of medicines was better in Vietnam than in 
the Philippines, especially with regard to insulin. This affected adherence as did a lack of patient 
education. As countries aim to provide health care to the majority of their populations through 
universal coverage, the challenge of diabetes cannot be neglected. Trying to achieve universal cover-
age in parallel to decentralization, national and local governments need adapted guidance for this.
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Introduction
“Diabetes is a major threat to global public health that is rapidly getting worse,”
1 and Asia will 
see the largest absolute increase from 66 993 000 to 99 401 000 estimated individuals with diabetes 
between 2007 and 2025.
2 Diabetes and other chronic conditions have now replaced communicable 
diseases as the most common causes of morbidity and mortality, with Asian countries having 
witnessed this “epidemiological transition” in a very short period of time.
3 This change in the 
burden of disease affects the functioning of health systems in moving from acute to chronic care.
4 
In 2008, it was reported that the shift of the leading causes of morbidity from communicable to 
noncommunicable diseases (NCDs) occurred in Vietnam.
5 In the Philippines, NCDs account for 
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6 of the top 10 causes of mortality.
6 This shift in burden is also linked to problems in delivery of 
care, with a study including the Philippines and Vietnam finding that more than half of the people 
with diabetes receiving care were not well controlled.
7
To address this change in disease burden and also identify the barriers to chronic care, a clear 
assessment of the health system is needed. It has been suggested that diabetes can be used as a 
tracer condition for the proper functioning of health systems and its ability to manage chronic 
conditions,
8,9 and therefore it was decided to assess the barriers to access to diabetes medicines 
and care in the Philippines and Vietnam.
The International Diabetes Federation estimates that the prevalence of diabetes in adults in the 
20 to 79 age group for Vietnam is 2.5% and in the Philippines 6.5%.
2 Local studies have shown 
prevalence rates of 2.7% and 4.4%
10 in urban areas in Vietnam, and the second National Diabetes 
Survey in the Philippines in 2002
11 found diabetes prevalence rates in the 20 to 65 age group to 
be 5.3% in the capital city and 4.8% in urban and rural areas. Besides this disease burden, diabetes 
is also a financial burden with cost estimates in 2007 for the Philippines and Vietnam being 
US$775 million and US$320 million, respectively.
2 It is estimated that these figures will increase 
to US$2.3 billion and US$1.1 billion for each country by 2025.
The Philippines and Vietnam are aiming to achieve universal health insurance coverage
12-17 
and have decentralized
18,19 the management of health to lower levels of the country’s administra-
tive structure. The Philippines is ranked 102 and Vietnam is ranked 114 out of 182 on the UNDP’s 
Human Development Index.
20 They have similar domestic population size with approximately 
86 million people. Gross national income per capita (in US dollars) is equal to US$3430 in the 
Philippines and US$2310 in Vietnam. The Philippines (male 68, female 71) has a lower life 
expectancy than Vietnam (male 72, female 75). Of total government expenditure, 6.4% was spent 
on health in the Philippines and 6.8% in Vietnam, with out of pocket health expenditure being 
higher in Vietnam, 86.1%, versus 80.3% in the Philippines of total expenditure on health.
21
The objective of the article is to analyze the results of 2 studies carried out in the Philippines
22,23 
and Vietnam
24 looking at the barriers to access to diabetes care and medicines and suggest recom-
mendations that may be applicable to other countries in Southeast Asia facing similar challenges.
Methods
The Rapid Assessment Protocol for Insulin Access (RAPIA)
25 was developed by the International 
Insulin Foundation and is structured as a multilevel assessment of the different elements that 
influence the access to diabetes care (see Table 1). The RAPIA draws on the principles of rapid 
assessment protocols, which have been used extensively to assess services for communicable 
diseases, including malaria, tuberculosis, and sexually transmitted diseases, for the purpose of 
developing interventions.
26-29 This methodology does not statistically analyze the health system 
by using representative samples but has as its aim to assess in a short time the situation with 
regard to diabetes care in a given country in order to provide different stakeholders recommenda-
tions for action.
The RAPIA is divided into 3 components. The first is the macro level, which is aimed at the 
ministerial levels, private sector, national diabetes association, central medical store, and educa-
tors. The meso level targets provincial health officers, “health care settings” (hospitals, clinics, 
health centers, etc), and pharmacies/dispensaries. Finally, in the micro level carers (health care 
workers and traditional healers) and people with diabetes are interviewed. The meso and micro 
levels are implemented in different areas chosen by local stakeholders to be representative of 
different geographical and socioeconomic situations within the country.
The questionnaires developed and the questions included in them follow each level of the path 
from the beginning with the purchase and importation of insulin and medicines to the country until 
these reach or fail to reach the patient. In parallel, the path of care is assessed. The questionnaires 
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serve as a guide and can be adapted to the country investigated. The information is gathered through 
the different questionnaires (qualitative and quantitative data), site visits, document reviews, and 
discussions.
Table 1. Levels of the RAPIA
25
Level Issues Addressed in RAPIA
Macro  
Ministry of Trade Trade issues (laws, barriers to trade)
  Trade infrastructure
Ministry of Finance Funding of health system
  Taxes on diabetes medicines
  Funding diabetes
Ministry of Health Funding of health system
  Organization of delivery of diabetes care and education
  Resources available for diabetes
  National programs for diabetes
  Pricing of insulin and medicines
  Distribution of insulin and medicines
  Funding for insulin and diabetes and education
  Tendering and purchase of insulin and medicines
Private sector Pricing of insulin and medicines
  Distribution of insulin and medicines
National diabetes association Issues with diabetes and insulin
Central medical store Tendering and purchase of insulin and medicines
  Distribution and storage of insulin and medicines
  Pricing of insulin and medicines
Educators Training of health care professionals with regard to diabetes
Meso  
Regional health organization Issues with diabetes in specific area
  Organization of care for patients with diabetes
Hospitals, clinics, health centers, 
dispensaries, and so on
Treatment and management of patients with diabetes
  Infrastructure present and/or lacking for diabetes care
  Access to appropriate tools for diagnosis and treatment
Regional medical store Distribution and storage of insulin and medicines
  Pricing of insulin and medicines
Laboratory Diagnosis of patients
Pharmacy/dispensary Distribution and storage of insulin and medicines
  Pricing of insulin and medicines
Micro  
Health workers Problems encountered in treatment of patients
  Training for diabetes care
  Infrastructure present and/or lacking for diabetes care
  Tools present and/or lacking (including education)
Traditional healers Problems encountered in treatment of patients
  Treatment of patients with diabetes
People with diabetes Access to treatment and education
  Cost of treatment
Abbreviation: RAPIA, Rapid Assessment Protocol for Insulin Access.
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Two studies were separately conducted around the same time in 2008. Local teams trained on 
how to use the tool carried out interviews. Both teams informed on and collaborated with each 
other. The Vietnam team, lead by DB, visited 4 areas and carried out 190 interviews. The Philippine 
team, lead by MH, visited 5 areas and carried out 359 interviews (see Table 2). Both teams approached 
respondents from different health administration levels (province, district, municipalities, and 
community) and different sectors (public and private). It was the main reason for the different 
sample sizes in these studies that more diabetes patients were interviewed in the Philippines to 
address diversity of patient choices in the country. Different facilities were visited to assess dia-
betes care with the main facilities viewed as a “center of excellence” for diabetes being surveyed 
as well as other main facilities. In addition, other facilities were surveyed with the research target-
ing the lowest-level facility where one would expect diabetes care to be delivered. For people 
with diabetes, interviews were either carried out on the day of the visit or interviewers returned 
the day when diabetes consultations were held.
Results
Provision of Diabetes Care
Diabetes care is mainly provided by hospitals with specialized care available at the provincial 
level in both countries. Most care for diabetes in Vietnam was provided in large urban areas where 
physicians working in tertiary referral facilities often saw patients for routine consultations. Due 
to a lack of knowledge of health care workers at lower levels of the health system, care for type 
1 diabetes in the Philippines and Vietnam was only provided in a limited number of facilities in 
main cities. Endocrinology and diabetology are relatively new specialties in Vietnam and therefore 
there are few doctors considered specialists in this field. In the Philippines, specialty training for 
endocrinology exists and a private nonprofit institute offers different courses in diabetes.
At the main tertiary facilities in Hanoi and Ho Chi Minh City, all staff have received special-
ized training in different aspects of diabetes care. At these facilities, nurses play a more active 
role in care and patient education because of this training. In the Philippines, specialists were 
concentrated in the provincial capital and usually run private clinics, but also offer some consulta-
tions in the public sector.
At provincial and general hospitals in Vietnam some doctors will have had some training in 
diabetes either from abroad or from specialists from Hanoi or Ho Chi Minh City. In Vietnam, the 
aim is to devolve diabetes care to the district level, but the main barrier to this policy is lack of 
trained health care workers. The Philippines has addressed this problem by having professional 
associations provide both health professionals and lay members with training courses for diabetes 
educators. Nutritionists and dieticians also play a role in diabetes management, whereas these 
specialties were lacking in Vietnam.
Guidance exists from the Ministry of Health in Vietnam as to which types of tests should be 
available to patients at different levels of the health system. There are licensing criteria in the 
Table 2. Number of Interviews Carried Out for the Studies in Vietnam and the Philippines
Country Area Macro Meso Micro Total
Philippines  4 56 299 359
Vietnam  Hanoi and North  6 45  50 101
Ho Chi Minh City and South  4 31  54  89
  Total Vietnam 10 76 104 190
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Philippines that include guidance on laboratory equipment. No issues with supplies of reagents 
or equipment were reported in Vietnam, unlike in the public sector in the Philippines where this 
was a problem.
Purchase and Supply of Diabetes Medicines
The Ministry of Health in Vietnam prepares guidance prices for different medicines, which are 
used by each facility to prepare their individual tenders. Some of these prices were up to 6 times 
higher than those available on the international market. The purchasing of branded medicines 
versus generics had an impact on expenditure of facilities in Vietnam and ultimately on the indi-
vidual and/or the insurance system. This information is detailed in Table 3. In the Philippines, 
prices for common diabetes medicines were found to be substantially higher than international 
benchmark prices as shown in Table 4.
Unlike in Vietnam, medicines for public facilities in the Philippines are procured through the 
public bidding process at each local government unit based on an annual procurement plan. The 
Philippine International Trading Corporation, a government-owned and controlled corporation, 
is responsible for “parallel medicines importation.” These medicines are sold to public hospitals 
and community medicines outlets at generally lower prices. This is part of the strategies led by 
the Department of Health to try to reduce medicines price.
In both countries, Glibenclamide and Metformin were available in the majority of hospital phar-
macies visited. In Vietnam, other oral medications and insulin were also readily available in the 
public and private sectors, but this was not the case in the public sector in the Philippines. In pediatric 
facilities, insulin was not readily available in the public sector in Vietnam and was only available at 
the main public hospital and in some private hospitals in each province visited in the Philippines.
Insulin and oral medicines for diabetes are subject to 5% import duty and 5% VAT in Vietnam.
30 
Mark-ups throughout the supply chain increase the price in the public sector for those without 
health insurance and the private sector. In the Philippines, medicines are subject to 5% custom 
duty and 12% VAT. Another factor affecting cost of medicines is the availability of generic versus 
branded products. In both countries, health care workers and people with diabetes stated their 
mistrust of generics.
Table 3. Price per Tablet Based on Public Sector Tenders and Brand Premium in Vietnam
23
Price in US$
 Brand 
Premium Medicine and Strength High Low Mean
Glibenclamide 5 mg 0.03 0.02 0.02
a
Glimepiride 2 mg 0.21 0.04 0.14 5.1
Glimepiride 4 mg 0.29 0.15 0.23 2.0
Metformin 500 mg 0.08 0.02 0.05 3.5
Metformin 850 mg 0.14 0.03 0.08 4.7
Metformin 1000 mg 0.16 0.08 0.13 2.0
Rosiglitazone 2 mg and Metformin 500 mg 0.50 0.22 0.32 2.3
Gliclazide 30 mg 0.12 0.04 0.08 3.0
Gliclazide 80 mg 0.12 0.04 0.07 3.0
Metformin 500 mg and Glibenclamide 2.5 mg 0.18 0.08 0.13 2.3
Metformin 500 mg and Glibenclamide 5 mg 0.44 0.09 0.24 4.9
Rosiglitazone 4 mg 0.96 0.96 0.96
b
aOnly generic versions.
bOnly branded versions.
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Cost of Diabetes Care for the Individual
People with type 2 diabetes in Vietnam who reported having insurance stated that cost of treatment 
was not a problem, but other costs such as transportation were sometimes a barrier, especially for 
people living away from major urban centers. Those without insurance described the financial burden 
of diabetes, especially type 1 diabetes, as the main obstacle to proper care. Consultation fees at public 
facilities are free or inexpensive, but the purchasing of medicines and paying for laboratory tests 
were the major barriers to regular care for the majority of respondents in the Philippines as these are 
not covered by PhilHealth benefits. Costs of the different aspects of care are detailed in Table 5.
The private sectors in Vietnam and the Philippines were extremely well supplied with medicines 
for diabetes. In the private sector in Vietnam and the Philippines, medicines were about 30% and 
300% more expensive, respectively, than in the public sector.
Information, Education, and Diabetes Associations
Printed information developed by hospitals and pharmaceutical companies was also available in both 
countries. The main factor identified as leading to a lack of patient education was shortage of time, 
with doctors needing to see many patients. Also the health insurance schemes do not cover patient 
education and counseling. This combined with the high cost of medicines led to poor adherence.
Different organizations involved with diabetes were present in both countries. In Vietnam, the 
Vietnam Diabetes Association is only for doctors and provides a chance for doctors to meet and 
discuss different issues surrounding diabetes. There is also a Diabetes Educators Association and 
anyone can join who has an interest in diabetes. These are mainly active in Hanoi and Ho Chi Minh City. 
Table 4. Median Purchase Price and International Reference Price of Oral Medicines for Diabetes in the 
Philippines
22
Medicine
Median Price 
US$ (per Tablet, 
per 10 mL Vial)
International 
Reference 
Price (US$)
34 Ratio
Metformin (500 mg) 0.11 0.021 5.1
Glibenclamide (5 mg) 0.16 0.005 32.0
Gliclazide (80 mg) 0.18 0.045 4.0
Mixed insulin (10 mL) 17.4 5.716 3.0
Isophane insulin (10 mL) 25.3 5.580 4.5
Regular insulin (10 mL) 26.1 5.480 4.8
Table 5. Costs of Different Aspects of Diabetes Care in the Philippines and Vietnam
22,23
Mean Cost of Aspect 
of Diabetes Care to 
the Individual (US$)
Insulin (per 
Month)
a, 
Median
Oral Medicines 
(per Month)
a, 
Median
Travel 
(per Visit), 
Median
Syringe 
(Unit), 
Median
Philippines 19.59 13.36 0.87 0.22
Vietnam  7.35 30.61 4.90 0.09
aIn the Philippine survey, actual monthly expenses for insulin and oral medicines were not asked. Monthly expenses 
here were calculated from unit prices and daily doses in patient answers. Calculation is based on an assumption that 
the patient takes medicines according to the prescription. In Vietnam, this is the cost per vial, including individuals 
who received insulin for free. For oral medicines this is cost per month, again including those who received all or part 
of their treatment for free.
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Diabetes clubs exist at different facilities with special diabetes clubs established for children with 
type 1 diabetes and their families. Their aim is to provide support and education to people with 
diabetes. These organizations are very dependent on health care workers at these facilities to man-
age their activities.
Diabetes-related activities varied among the surveyed provinces in the Philippines. In 2 of the 
5 areas visited, no diabetes patient support club existed. Establishing and continuing a club seemed 
to rely on the availability and leadership of physicians in the area. Clubs and their organization 
varied with some clubs officially registered as an organization and others just gathering patients 
on a diabetes clinic day. Some clubs routinely (monthly or annually) also collected money from 
members to support activities.
Policy Environment
A decision by the Vietnamese Prime Minister in 2002 approved a program to control NCDs for 
the period of 2002 to 2010. This led to a preliminary National Plan for Diabetes prepared for the 
years 2006 to 2010.
31 The plan highlighted the increasing burden of diabetes in Vietnam and the 
challenges that Vietnam will face because of this.
Because of the increase in burden of lifestyle-related diseases in the Philippines, the importance 
of healthy lifestyles has been recognized by the Department of Health. This led to the creation of 
the National Centre for Disease Prevention and Control in 2000 and a diabetes-specific office at 
this center. Reduction of mortality and morbidity from lifestyle-related diseases, including diabetes, 
is listed as one of the goals in “the National Objectives for Health 2005-2010.” Because of decen-
tralization, the level of commitment to implement the program varied among the local government 
units visited.
The Vietnamese national target program for diabetes and hypertension has recently been 
approved and receives special funding and attention from the central government. As in the Philip-
pines, because of decentralization, curative activities not effectively linked to promotion and 
prevention activities, and hospital autonomy, the impact of policy decisions at the central level 
on actual practice in Vietnam is hard to quantify.
In the Philippines, many policies have focused on the issue of medicine prices (eg, Generics 
Act of 1988 and Universally Accessible Cheaper and Quality Medicines Act of 2008). Because 
of a long history of failure in reducing medicine prices, people interviewed were skeptical about 
the effectiveness of these policies. No such policies have been developed in Vietnam.
Discussion
This comparative study is based on the use of similar methods in Vietnam and the Philippines car-
ried out during the same period of time and therefore allow comparison of 2 similar health systems 
in Asia.
In both countries, the average cost of overall diabetes care was extremely high, thus having a 
direct impact on adherence with cost of treatment and medicines being a major barrier. In Vietnam, 
the average monthly cost of transportation and medicines alone equaled US$34.41, equivalent to 
18% of monthly per capita gross national income. The cost of medicines in both the Philippines 
and Vietnam are passed on to the individual or the insurance system, and therefore procurement 
practices will affect this cost. Poor procurement practices were present in both countries, leading 
to high costs of medicines compared with the international market prices as detailed in studies 
carried out by the World Health Organization and Health Action International.
32
Another factor affecting adherence in both countries was inadequate patient education because 
of a variety of factors, including overburdened staff, materials not adapted to sociocultural context, 
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lack of trained staff, and a lack of involvement of nurses and other health personnel in managing 
diabetes.
Once people have registered with the respective insurance schemes these schemes seem to 
work well, but are often viewed as confusing to register with in the Philippines and to not always 
be value for money in both countries. Some people in Vietnam said that even though they had or 
were eligible for health insurance, they preferred to pay out of pocket as they felt they received 
better service. Health insurance and the aim of achieving universal coverage are an opportunity 
and a threat to improving the organization of the health system. It is an opportunity as the health 
insurance scheme could regulate referrals, tests, and medicines being available at different facili-
ties and relieve the burden of cost to the individual. However, this may also have a negative impact 
as hospitals will keep people in their patient population as they are viewed as a source of income.
This also affects referral systems, which are important for long-term care because as seen in 
Vietnam, hospitals are individual entities whose sources of income comes from the government 
(central and local), out of pocket payments, and payments from insurance. In addition, away from 
major cities diabetes care is problematic because of a lack of specialized staff as well as inadequate 
infrastructure. With decentralization and the organization of the health system, each facility and 
its relationship with other facilities higher and lower in the overall system may not be clear. This 
affects referrals, especially from provinces to larger urban centers.
Conclusion
As countries in Asia develop the means to provide health care to the majority of their populations, 
the challenge of diabetes and other NCDs cannot be neglected. These conditions will not only 
burden individuals but also the health systems and economies of these countries. A recent strategy 
published by the World Health Organization
33 addresses both the issue of high out of pocket pay-
ments and how these act as a major barrier to achieving universal coverage in Asia. This strategy 
document provides clear guidance on how to achieve universal coverage, but to address the 
increasing burden of diabetes and NCDs, creativity is needed. In this changing disease burden, 
the role of health insurance should be increased from one that simply reimburses medical care to 
one that actively tries to prevent chronic diseases. Linking this approach to decentralization, 
national and local governments need to adapt guidance from the central level to effectively address 
a health concern that affects all levels of society and therefore clearly define their role in the 
struggle to prevent and deal with the increasing burden of diabetes and other NCDs.
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